When an exosome batch arrives, the first question is often “how many particles came?” Yet in biological-derived products, batch identity, temperature history, and storage conditions carry equal weight. Exosomes are extracellular vesicles in the 30–150 nm band; they carry protein, lipid, and nucleic acid cargo. That cargo varies with source cell, isolation method, and production batch; a temperature excursion must be interpreted together with the same batch’s characterisation data. In VascularVita’s stem cell and exosome range, the technical file, lot analysis and cold-chain records are reviewed together in institutional supply discussions. This article summarises what cold-chain records mean in an exosome batch, how to interpret storage conditions, and which document headings complement evaluating an exosome technical dossier.
Cold chain: the logistics dimension of batch integrity
Cold chain is the logistics and recording system that keeps a product within a defined temperature range from the manufacturing site to the clinical or warehouse point. In sterile interventional devices, packaging integrity is foremost; in exosomes and similar biological preparations, the thermal profile is an inseparable part of batch identity. A batch characterisation report — size distribution, marker profile, protein concentration — is measured at production; warming or freeze–thaw cycles during delivery can invalidate that data or at least require reassessment.
In B2B supply, cold chain does not close with “there were ice packs in the shipping box.” Between manufacturer, logistics partner, and receiving institution, temperature log, excursion duration, and intervention protocol must be written. Extracellular vesicles are sensitive to membrane integrity; aggregation, cargo loss, and contamination risk rise with temperature fluctuation. The purchasing team therefore compares storage instructions in the technical file with the logistics SLA; if there is mismatch, written explanation from the manufacturer or distributor is requested before batch acceptance.
Cold-chain records: what to look for
A cold-chain record is the document set reviewed at or after delivery. Format varies between institutions, yet the fields below repeat on B2B checklists:
- Target temperature range — storage temperature stated in manufacturer IFU or technical file (for example 2–8 °C or −80 °C); target range is batch-specific, not generalised.
- Data logger output — continuous or interval measurement from shipment start to delivery; timestamp and sensor identity.
- Excursion records — time outside target range, maximum/minimum temperature, and manufacturer excursion assessment note.
- Chain-of-custody handover points — manufacturing site, transit hub, customs hold, last-mile delivery; responsible party and transfer time at each handover.
- Packaging verification — vacuum panel, phase-change material (PCM), or dry ice use; packaging damage or humidity indicator status.
Missing records are not compensated by verbal “it was kept cold.” In multi-stop international shipments, customs delay is the most frequent excursion point; that period must be visible in logger data. Hospital warehouse staff match logger data to batch number and expiry at acceptance; mismatched records stop stock entry.
Electronic monitoring and alarm thresholds
Advanced logistics use real-time monitoring platforms; alarm threshold is derived from manufacturer instructions. When an alarm triggers, intervention — adding coolant, changing route, or stopping shipment — is recorded per protocol. On the purchasing side the question is: “Was there an excursion, and if so, does the manufacturer still release this batch?” The answer is sought in the technical file or batch release certificate.
Storage: temperature, location, and duration
Storage conditions are limited to manufacturer-approved temperature and duration. Exosome preparations are usually kept in deep freezer (−80 °C or stated equivalent) or refrigerator (2–8 °C); which temperature applies is batch-specific and IFU is not exceeded. The headings below are considered together in warehouse planning:
- Freeze–thaw cycles — repeated freeze–thaw is prohibited or limited by count in most batches; label and IFU state that limit.
- Shelf life and expiry — storage duration from manufacture date; the in-use period after opening is a separate item.
- Location and access — shelf map in −80 °C cabinet, emergency generator, and temperature alarm; for 2–8 °C, door-opening frequency and air circulation.
- Cross-contamination — separation of biological safety cabinet from general refrigerator; batch-level location label.
Warehouse staff manage exosome batches with the same discipline as medical device lot tracking, using FEFO (first expired, first out). Lots nearing expiry are matched to clinical use plans; expired lots enter disposal or return procedure. Lot traceability in sterile dressings is summarised under UDI and lot headings in medical device technical documentation; the same logic continues with batch number and temperature history for biological batches.
Cold-chain section in the technical file
Evaluating an exosome technical dossier covered source cell, characterisation, and batch consistency. Cold chain and storage are the logistics and quality-assurance continuation of that file. Additional headings sought in the technical file are:
- Approved storage and shipping instruction — temperature, humidity upper limit, maximum transit time.
- Stability data — analytical results supporting shelf life under stated conditions; whether retesting is required after excursion.
- Batch release criteria — control point where characterisation, sterility, endotoxin, and temperature history are evaluated together.
- Deviation management — manufacturer risk assessment and use decision when temperature limits were exceeded.
- Label and logistics symbols — “store frozen,” “do not freeze,” transport temperature range; alignment with ISO 15223 symbols.
The MISEV (Minimal Information for Studies of Extracellular Vesicles) framework primarily standardises characterisation reporting; in commercial supply, comparing batches becomes possible when that report is presented together with cold-chain records. Biological mechanism headings in the literature — immunomodulation, angiogenesis, cell migration — describe the field in general terms; clinical outcome of a specific lot is not automatically derived from those headings. Supply decisions rest on measurable data in the file and logistics assurance.
Product scope and institutional supply terms are summarised on the stem cell and exosome page. Intercellular communication and extracellular vesicle context is covered in the longevity series in altered intercellular communication and aging; vascular and tissue perfusion notes are in vascular health and healthspan.
Delivery acceptance: practical sequence
When an exosome batch is accepted at the door, sequence usually runs as follows:
- Outer packaging check — damage, humidity indicator, coolant condition.
- Label and batch number — match to order line and lot in technical file.
- Data logger download — target temperature range and excursion summary.
- Manufacturer excursion assessment — written approval or restricted-use note if present.
- Warehouse placement — immediate transfer to approved temperature zone; temperature history added to acceptance record.
This flow resembles UDI triple matching in interventional stock acceptance; the difference is that in a biological batch, temperature history is also an identity component. Missing logger or unexplained excursion places the batch in quarantine until manufacturer correspondence is complete before clinical use.
Common criteria in institutional supply
In VascularVita discussions, an exosome batch is evaluated as one package: characterisation report, sterility data, and cold-chain record. Distribution partner warehouse capacity (is −80 °C backed up?), transit time, and recall procedure are agreed in the same technical meeting. Before any comparison table, each batch’s own IFU and temperature profile is reviewed; products with different source cells or isolation methods are not forced into one row.
Cold-chain discipline is a visible component of reliable supply in regenerative products. When records are not kept, however detailed the batch analysis, uncertainty remains after delivery; in B2B supply the file is completed rather than accepting that uncertainty.
Sources
- Théry C, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018). J Extracell Vesicles. 2018. doi:10.1080/20013078.2018.1535750
- Welsh JA, et al. MISEV2023: Updated guidelines for studies of extracellular vesicles. J Extracell Vesicles. 2024. doi:10.1002/jev2.12404
- WHO. Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products. who.int
- Pansky B, Roisman A. Cold chain management of biological samples and reagents. Best practice in biobanking logistics (review). PubMed — EV storage literature
- VascularVita: Exosome technical dossier · Stem cell and exosome · Longevity